DUBLIN--(BUSINESS WIRE)-- Research and Markets (http://www.researchandmarkets.com/research/vbsgl5/global_prostate) has announced the addition of the "Global Prostate Cancer Epidemiology and Patient Flow Analysis - 2012" report to their offering.
Fore Pharma announced the results of its Prostate Cancer patient population study in a new report Global Prostate Cancer Epidemiology and Patient Flow Analysis - 2012'. The report provides insights into Prostate Cancer epidemiology, Prostate Cancer diagnosed patients, and Prostate Cancer treatment rate for top seven pharmaceutical markets. The study measures key indicators such as prevalence of Prostate Cancer derived from epidemiological analysis, percentage of patients diagnosed with Prostate Cancer, and percentage of patients treated with Prostate Cancer therapy.
The study helps executives estimate Prostate Cancer market potential, assess unmet need, develop drug forecasting models, and build population-based health management frameworks. The information presented in this study is used to evaluate market opportunities, effectively identify target patient population, and align marketing decisions.
The report provides estimates and forecasts of Prostate Cancer prevalence, Prostate Cancer diagnosis rate, and Prostate Cancer treatment rate for the period 2012-2019. The information is presented by leading geographies including the US, Germany, France, Spain, Italy, UK, and Japan. The study design is based on collection and interpretation of data from registries, scientific journals and literatures, government databases and other secondary sources.
For more information visit http://www.researchandmarkets.com/research/vbsgl5/global_prostate
Source: Research and Markets